{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/BIOA/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T03:42:03.235Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1592,"canonical_name":"BioAge Labs, Inc.","cik":"0001709941","uei":null,"lei":null,"duns":null,"ticker":"BIOA"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":25,"clinical":2},"count":27,"timeline":[{"ts":"2026-10-02","kind":"sec.filing","form_type":"8-K","title":"8-K — BioAge Labs, Inc. — 2026-10-02","url_slug":"/sec/cik-0001709941/8-k/0001193125-26-412300","accession_number":"0001193125-26-412300","importance":35},{"ts":"2026-09-10","kind":"clinical.trial","reporter":"BioAge Labs, Inc.","title":"A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07656727","excerpt":"[\"Obesity and Cardiovascular Risk\"]","importance":45},{"ts":"2026-09-10","kind":"clinical.trial","reporter":"BioAge Labs, Inc.","title":"A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07812090","excerpt":"[\"Diabetic Macular Edema (DME)\"]","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — BioAge Labs, Inc. — 2026-08-05","url_slug":"/sec/cik-0001709941/10-q/0001193125-26-335407","accession_number":"0001193125-26-335407","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — BioAge Labs, Inc. — 2026-08-05","url_slug":"/sec/cik-0001709941/8-k/0001193125-26-335368","accession_number":"0001193125-26-335368","importance":35},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — BioAge Labs, Inc. — 2026-07-01","url_slug":"/sec/cik-0001709941/4/0001836297-26-000005","accession_number":"0001836297-26-000005","importance":30},{"ts":"2026-06-30","kind":"sec.form144","reporter":"Barton Shane","title":"Officer","shares":20216,"usd_value":509177,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001959173-26-004979","importance":40.101835466},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":20216,"price_per_share":25.1868,"usd_value":509176,"security_title":"Common Stock","importance":35.5091763488},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — BioAge Labs, Inc. — 2026-06-30","url_slug":"/sec/cik-0001709941/144/0001959173-26-004979","accession_number":"0001959173-26-004979","importance":30},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":4290,"price_per_share":10.85,"usd_value":46547,"security_title":"Common Stock","importance":15.0465465},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":7861,"price_per_share":4.38,"usd_value":34431,"security_title":"Common Stock","importance":15.03443118},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":4000,"price_per_share":8.39,"usd_value":33560,"security_title":"Common Stock","importance":15.03356},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":4065,"price_per_share":4.3,"usd_value":17480,"security_title":"Common Stock","importance":15.0174795},{"ts":"2026-06-29","kind":"sec.form144","reporter":"Barton Shane","title":"Officer","shares":42350,"usd_value":1067578,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001959173-26-004955","importance":40.213515512},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":42350,"price_per_share":25.2084,"usd_value":1067576,"security_title":"Common Stock","importance":36.06757574},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — BioAge Labs, Inc. — 2026-06-29","url_slug":"/sec/cik-0001709941/144/0001959173-26-004955","accession_number":"0001959173-26-004955","importance":30},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":9301,"price_per_share":10.85,"usd_value":100916,"security_title":"Common Stock","importance":15.10091585},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":14198,"price_per_share":4.38,"usd_value":62187,"security_title":"Common Stock","importance":15.06218724},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":7261,"price_per_share":8.39,"usd_value":60920,"security_title":"Common Stock","importance":15.06091979},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Barton Shane","title":"Principal Accounting Officer","shares":8958,"price_per_share":4.3,"usd_value":38519,"security_title":"Common Stock","importance":15.0385194},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — BioAge Labs, Inc. — 2026-06-12","url_slug":"/sec/cik-0001709941/8-k/0001193125-26-268518","accession_number":"0001193125-26-268518","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — BioAge Labs, Inc. — 2026-06-12","url_slug":"/sec/cik-0001709941/4/0001771213-26-000004","accession_number":"0001771213-26-000004","importance":30},{"ts":"2026-06-12","kind":"sec.filing","form_type":"4","title":"4 — BioAge Labs, Inc. — 2026-06-12","url_slug":"/sec/cik-0001709941/4/0001840663-26-000002","accession_number":"0001840663-26-000002","importance":30},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — BioAge Labs, Inc. — 2026-05-15","url_slug":"/sec/cik-0001709941/schedule-13g-a/0001193125-26-226770","accession_number":"0001193125-26-226770","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"10-Q","title":"10-Q — BioAge Labs, Inc. — 2026-05-08","url_slug":"/sec/cik-0001709941/10-q/0001193125-26-213466","accession_number":"0001193125-26-213466","importance":45},{"ts":"2026-05-08","kind":"sec.filing","form_type":"8-K","title":"8-K — BioAge Labs, Inc. — 2026-05-08","url_slug":"/sec/cik-0001709941/8-k/0001193125-26-213472","accession_number":"0001193125-26-213472","importance":35},{"ts":"2026-04-27","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — BioAge Labs, Inc. — 2026-04-27","url_slug":"/sec/cik-0001709941/schedule-13g/0002012383-26-001675","accession_number":"0002012383-26-001675","importance":55}]}